Skip to Content
Merck
CN

B3686

BAY U6751 hydrate

solid, ≥98% (HPLC)

Synonym(s):

4-(2-Chlorophenyl)-1-ethyl-1,4-dihydro-6-methyl-2,3,5-pyridinetricarboxylic acid 5-isopropyl ester disodium salt hydrate

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C20H20ClNNa2O6 · xH2O
CAS Number:
114290-51-6
Molecular Weight:
451.81 (anhydrous basis)
NACRES:
NA.77
PubChem Substance ID:
24891730
UNSPSC Code:
12352200
MDL number:
MFCD08705410

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Quality Level

100

InChI

1S/C20H22ClNO6.2Na.H2O/c1-5-22-11(4)14(20(27)28-10(2)3)15(12-8-6-7-9-13(12)21)16(18(23)24)17(22)19(25)26;;;/h6-10,15H,5H2,1-4H3,(H,23,24)(H,25,26);;;1H2/q;2*+1;/p-2

SMILES string

[Na+].[Na+].[H]O[H].CCN1C(C)=C(C(c2ccccc2Cl)C(C([O-])=O)=C1C([O-])=O)C(=O)OC(C)C

InChI key

QECLOEJXLYHXNF-UHFFFAOYSA-L

assay

≥98% (HPLC)

form

solid

storage condition

protect from light

color

white

solubility

H2O: >8 mg/mL

originator

Bayer

storage temp.

2-8°C

Related Categories

Biochem/physiol Actions

BAY U6751 is a glycogen phosphorylase inhibitor. Formed from the prodrug, BAYR3401. BAY U6751 exists as the enantiomeric mixture. BAY W1807 is the active metabolite.
BAY W1807, the active metabolite of BAY R3401, inhibits muscle glycogen phosphorylase a and b. In gel-filtered liver extracts, racemic BAY U6751 (containing active BAY W1807) was tested for inhibition of phosphorylase in the glycogenolytic (in which only phosphorylase a is active). In liver extracts, BAY U6751 (0.9-36 μmol/L) inhibited glycogen synthesis by phosphorylase b (notwithstanding the inclusion of AMP), but not by phosphorylase a. Inhibition of phosphorylase-a-catalyzed glycogenolysis was partially relieved by AMP (500 μmol/L). BAY U6751 facilitated phosphorylase-a dephosphorylation. Isolated hepatocytes and perfused livers were tested for BAY R3401-induced changes in phosphorylase-a:b ratios and glycogenolytic output.

Features and Benefits

This compound was developed by Bayer. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Disclaimer

Light sensitive. Store in amber vials.

pictograms

Exclamation mark
GHS07

signalword

Warning

Hazard Classifications

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

target_organs

Respiratory system

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Gloves

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000075371
0000075366
046K4704

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service